Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 122

    1.

    A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors.

    Inbar-Rozensal D, Castiel A, Visochek L, Castel D, Dantzer F, Izraeli S, Cohen-Armon M.

    Breast Cancer Res. 2009;11(6):R78. Epub 2009 Nov 9.

    PMID:
    19891779
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?

    Frizzell KM, Kraus WL.

    Breast Cancer Res. 2009;11(6):111. Epub 2009 Nov 26.

    PMID:
    20017885
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    3.

    Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest.

    Wesierska-Gadek J, Schloffer D, Gueorguieva M, Uhl M, Skladanowski A.

    Cancer Res. 2004 Jul 1;64(13):4487-97.

    PMID:
    15231658
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.

    Tentori L, Muzi A, Dorio AS, Scarsella M, Leonetti C, Shah GM, Xu W, Camaioni E, Gold B, Pellicciari R, Dantzer F, Zhang J, Graziani G.

    Curr Cancer Drug Targets. 2010 Jun;10(4):368-83.

    PMID:
    20464779
    [PubMed - indexed for MEDLINE]
    5.

    The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.

    Smith LM, Willmore E, Austin CA, Curtin NJ.

    Clin Cancer Res. 2005 Dec 1;11(23):8449-57.

    PMID:
    16322308
    [PubMed - indexed for MEDLINE]
    Free Article
    6.

    Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.

    Shibata H, Miuma S, Saldivar JC, Huebner K.

    Cancer Sci. 2011 Oct;102(10):1882-8. Epub 2011 Jul 21.

    PMID:
    21707865
    [PubMed - indexed for MEDLINE]
    7.

    Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors.

    Efimova EV, Mauceri HJ, Golden DW, Labay E, Bindokas VP, Darga TE, Chakraborty C, Barreto-Andrade JC, Crawley C, Sutton HG, Kron SJ, Weichselbaum RR.

    Cancer Res. 2010 Aug 1;70(15):6277-82. Epub 2010 Jul 7.

    PMID:
    20610628
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    8.

    The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.

    De Soto JA, Wang X, Tominaga Y, Wang RH, Cao L, Qiao W, Li C, Xu X, Skoumbourdis AP, Prindiville SA, Thomas CJ, Deng CX.

    Int J Biol Sci. 2006;2(4):179-85. Epub 2006 Jun 10.

    PMID:
    16810332
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    9.

    Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.

    Comen EA, Robson M.

    Cancer J. 2010 Jan-Feb;16(1):48-52. Review.

    PMID:
    20164690
    [PubMed - indexed for MEDLINE]
    10.

    2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces oxidative stress, DNA strand breaks, and poly(ADP-ribose) polymerase-1 activation in human breast carcinoma cell lines.

    Lin PH, Lin CH, Huang CC, Chuang MC, Lin P.

    Toxicol Lett. 2007 Aug;172(3):146-58. Epub 2007 Jun 16.

    PMID:
    17669606
    [PubMed - indexed for MEDLINE]
    11.

    Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

    Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJ.

    J Natl Cancer Inst. 2004 Jan 7;96(1):56-67.

    PMID:
    14709739
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy.

    Simbulan-Rosenthal CM, Rosenthal DS, Luo R, Li JH, Zhang J, Smulson ME.

    Nucleic Acids Res. 2001 Feb 1;29(3):841-9.

    PMID:
    11160908
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    13.

    Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components.

    Tentori L, Portarena I, Vernole P, De Fabritiis P, Madaio R, Balduzzi A, Roy R, Bonmassar E, Graziani G.

    Cancer Chemother Pharmacol. 2001 Apr;47(4):361-9.

    PMID:
    11345654
    [PubMed - indexed for MEDLINE]
    14.

    PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.

    Peralta-Leal A, Rodríguez-Vargas JM, Aguilar-Quesada R, Rodríguez MI, Linares JL, de Almodóvar MR, Oliver FJ.

    Free Radic Biol Med. 2009 Jul 1;47(1):13-26. Epub 2009 Apr 10. Review.

    PMID:
    19362586
    [PubMed - indexed for MEDLINE]
    15.

    Mechanism of early biphasic activation of poly(ADP-ribose) polymerase-1 in response to ultraviolet B radiation.

    Vodenicharov MD, Ghodgaonkar MM, Halappanavar SS, Shah RG, Shah GM.

    J Cell Sci. 2005 Feb 1;118(Pt 3):589-99. Epub 2005 Jan 18.

    PMID:
    15657079
    [PubMed - indexed for MEDLINE]
    Free Article
    16.

    Hypoglycemic neuronal death and cognitive impairment are prevented by poly(ADP-ribose) polymerase inhibitors administered after hypoglycemia.

    Suh SW, Aoyama K, Chen Y, Garnier P, Matsumori Y, Gum E, Liu J, Swanson RA.

    J Neurosci. 2003 Nov 19;23(33):10681-90.

    PMID:
    14627653
    [PubMed - indexed for MEDLINE]
    Free Article
    17.

    The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.

    Miknyoczki S, Chang H, Grobelny J, Pritchard S, Worrell C, McGann N, Ator M, Husten J, Deibold J, Hudkins R, Zulli A, Parchment R, Ruggeri B.

    Mol Cancer Ther. 2007 Aug;6(8):2290-302.

    PMID:
    17699724
    [PubMed - indexed for MEDLINE]
    Free Article
    19.

    Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer.

    Comen EA, Robson M.

    Oncology (Williston Park). 2010 Jan;24(1):55-62. Review.

    PMID:
    20187322
    [PubMed - indexed for MEDLINE]
    20.

    Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors.

    Eltze T, Boer R, Wagner T, Weinbrenner S, McDonald MC, Thiemermann C, Bürkle A, Klein T.

    Mol Pharmacol. 2008 Dec;74(6):1587-98. Epub 2008 Sep 22.

    PMID:
    18809672
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk